Aurobindo Pharma reported a fire at its Penicillin-G facility in Kakinada SEZ, damaging ancillary equipment but sparing core ...

Aurobindo Pharma subsidiary Eugia Pharma Specialities has received final approval from the U.S. Food and Drug Administration (U.S. FDA) to manufacture and market Dasatinib Tablets in different ...

Aurobindo Pharma share price has gained 4% in one month, but the stock has dropped nearly 10% on a year-to-date (YTD) basis.

Aurobindo Pharma subsidiary CuraTeQ Biologics’ biosimilar for breast cancer has been recommended for marketing authorisation by the Committee for Medicinal Products for Human Use of the European ...

Pharma stocks such as Sun Pharma, Aurobindo Pharma, Dr Reddy's Lab, Cipla, Gland Pharma, Zydus Lifesciences and Lupin would be in action on Friday after the US President Donald Trump halted ...

On Thursday's session Nifty Pharma surged nearly 4% with Gland Pharma, Lupin, Aurobindo Pharma, Natco Pharma, Sun Pharmaceutical Industries leading the gains. Rajesh Bhosale, Equity Technical and ...

Aurobindo's manufacturing operations have once again landed the Indian drugmaker in hot water with the U.S. FDA. | ...

Gland Pharma topped the losses with a drop of almost 6 per cent, followed by Aurobindo Pharma, which fell by almost 5 per cent. Biocon's shares fell more than 4 per cent, and Sun Pharma, Lupin, Laurus ...

Brokerages CLSA and Citi pointed out that Aurobindo Pharma (48 per cent), Zydus (47 per cent), and Dr Reddy’s (46 per cent) have higher revenue mix from the US. BNP Paribas analysts see a 1-2 ...

Nifty Pharma dropped 6% during Friday's session following comments from US President Donald Trump, who indicated that the pharmaceutical sector is being categorized separately and that he would be ...

Aurobindo Pharma Ltd, Gland Pharma Ltd, Lupin Ltd and Dr Reddy's Labs Ltd led pharma sector gainers on Thursday, as despite levying a 27 per cent tariff on India overnight, the Trump ...

Aurobindo Pharma announced that its subsidiary CuraTeQ Biologics has received successful trial results for its new bone treatment medicine. The drug, called BP16, is a biosimilar of an existing ...